EDIT Editas Medicine, Inc.
Price Chart
Executive Summary
Editas Medicine priced a dilutive underwritten public offering of 55.6M shares and warrants at $2.25 per unit, raising ~$125M in gross proceeds (before expenses). The offering represents massive dilution of approximately 67% of current shares outstanding, signaling urgent capital needs for a pre-revenue biotech with a market cap of $270M.
Key Financial Metrics
Actionable Insight
Massive dilutive offering signals acute capital needs for a pre-revenue gene editing company. Expect significant downward pressure on EDIT shares as the market prices in the dilution. Monitor for any potential activist response or further financing needs; the warrant structure ties to EDIT-401 Phase 1 data, creating a binary catalyst but with severe near-term dilution.
Key Facts
- Offering of 55,555,556 shares of common stock and accompanying warrants to purchase an equal number of shares at a combined price of $2.25 per unit.
- Expected gross proceeds of approximately $125.0 million (excluding warrant exercise).
- Warrants have an exercise price of $3.50 per share, exercisable immediately, expiring 30 days after Phase 1 data for EDIT-401 or 3 years.
- Offering represents roughly 67% dilution based on current shares outstanding (implied from $270M market cap and $2.25 price).
- Underwriters include Cantor Fitzgerald and Wells Fargo Securities; offering expected to close on May 27, 2026.
Financial Impact
Dilution of approximately 67% of current shares outstanding, raising $125M in gross proceeds. Additional $194.4M possible if warrants exercised.
Risk Factors
- Extreme dilution of ~67% will likely crush stock price in the near term.
- Warrant overhang could pressure shares further if exercised.
- Pre-revenue status and reliance on pipeline (EDIT-401) for future value creation.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301169 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $2.49 awaiting T+5 | awaiting T+5 | — | $2.50 (+0.60%) |
|
May 26, 2026
17d ago
|
424B5
| $3.57 $2.82 | ▲ +21.01% | ▲ +22.22% | $2.50 (+29.97%) |
|
May 26, 2026
17d ago
|
8-K
| $3.57 $2.82 | ▲ +21.01% | ▲ +22.22% | $2.50 (+29.97%) |
|
May 26, 2026
18d ago
|
Press Release
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
8-K
| $3.08 $3.34 | ▲ +8.44% | ▲ +7.36% | $2.50 (−18.83%) |
|
May 26, 2026
18d ago
|
424B5
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
Press Release
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
Press Release
| $3.08 $2.82 | ▼ −8.44% | ▼ −9.65% | $2.50 (−18.83%) |
|
May 14, 2026
4w ago
|
8-K
| $2.85 $2.67 | ▼ −6.32% | ▼ −5.60% | $2.50 (−12.28%) |
|
May 14, 2026
4w ago
|
Press Release
| $2.85 $2.67 | ▼ −6.32% | ▼ −5.60% | $2.50 (−12.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access